Metacrine, Inc. will halt its non-alcoholic steatohepatitis (NASH) research and development after unveiling mixed Phase IIa data for FXR agonist MET642 in NASH patients. Now, the San Diego firm says it will move the same compound into inflammatory bowel disease (IBD), with a Phase II study in ulcerative colitis expected to begin during the first half of 2022.
This major and seemingly sudden switch in therapeutic focus for Metacrine led analysts to lower their valuations for the biotech to little more than cash on hand. Several noted that preclinical data suggest potential utility for the FXR agonist class in IBD, but no clinical data has been generated to back up the hypothesis
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?